I think combination therapy is coming; it’s just a question of which combinations,’ says Arthur Kavanaugh, MD.

J&J’s IL-23 inhibitor Tremfya (guselkumab), meanwhile, has also been filed for UC and Crohn’s, with a decision due in the coming months, although, AstraZeneca shelved its own drug in the class ...